SEC Comment Letter 0000000000-24-006296 to NEKTAR THERAPEUTICS (NKTR)
NEKTAR THERAPEUTICS
Date: May 31, 2024 · CIK: 0000906709 · Accession: 0000000000-24-006296
AI Filing Summary & Sentiment
File numbers found in text: 333-279760
Letter
United States securities and exchange commission logo May 31, 2024 Mark Wilson General Counsel Nektar Therapeutics 455 Mission Bay Boulevard South San Francisco, CA 94158 Re:Nektar Therapeutics Registration Statement on Form S-3 Filed May 28, 2024 File No. 333-279760 Dear Mark Wilson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Mitchell Bloom
Show Raw Text
United States securities and exchange commission logo
May 31, 2024
Mark Wilson
General Counsel
Nektar Therapeutics
455 Mission Bay Boulevard South
San Francisco, CA 94158
Re:Nektar Therapeutics
Registration Statement on Form S-3
Filed May 28, 2024
File No. 333-279760
Dear Mark Wilson:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Mitchell Bloom